Background-Diabetics remain at high risk of cardiovascular disease and mortality despite advancements in medical therapy. Noninvasive cardiac risk profiling is often more difficult in diabetics owing to the prevalence of silent ischemia with unrecognized myocardial infarction, reduced exercise capacity, nondiagnostic electrocardiographic changes, and balanced ischemia from diffuse epicardial coronary atherosclerosis and microvascular dysfunction. Methods and Results-A consecutive cohort of 173 patients with diabetes mellitus (mean age, 61.7±11.9 years; 37% women) with suspected myocardial ischemia underwent stress perfusion cardiac magnetic resonance imaging. Patients were evaluated for adverse cardiac events after cardiac magnetic resonance imaging with mean follow-up time of 2.9±2.5 years. Mean hemoglobin A1c for the population was 7.9±1.8%. Primary end point was a composite of cardiac death and nonfatal myocardial infarction. Diabetics with no inducible ischemia (n=94) experienced an annualized event rate of 1.4% compared with 8.2% (P=0.0003) in those with inducible ischemia (n=79). Diabetics without late gadolinium enhancement or inducible ischemia had a low annual cardiac event rate (0.5% per year). The presence of inducible ischemia was the strongest unadjusted predictor (hazard ratio, 4.86; P<0.01) for cardiac death and nonfatal myocardial infarction. This association remained robust in adjusted stepwise multivariable Cox regression analysis (hazard ratio, 4.28; P=0.02). In addition, categorical net reclassification index using 5-year risk cutoffs of 5% and 10% resulted in reclassification of 43.4% of the diabetic cohort with net reclassification index of 0.38 (95% confidence interval, 0.20-0.56; P<0.0001). Conclusions-Stress perfusion cardiac magnetic resonance imaging provided independent prognostic utility and effectively reclassified risk in patients with diabetes mellitus referred for ischemic assessment. Further evaluation is required to determine whether a noninvasive imaging strategy with cardiac magnetic resonance imaging can favorably affect downstream outcomes and improve cost-effectiveness of care in diabetics. (Circ Cardiovasc Imaging. 2016;9:e004136.
D iabetes mellitus remains one of the leading causes of mortality and morbidity despite advancements in medical therapy, with prevalence continuing to increase worldwide. 1 Diabetes mellitus is considered a coronary heart disease risk equivalent, because patients with diabetes mellitus without any history of myocardial infarction (MI) experience elevated risk of cardiac death and recurrent nonfatal MI similar to patients with established coronary artery disease (CAD). 2, 3 Unfortunately, noninvasive risk assessment of patients with diabetes mellitus remains challenging owing to multiple factors, including more advanced disease at the time of presentation, limited exercise capacity because of peripheral arterial disease and microvascular complications, and increased prevalence of silent MI and multivessel coronary disease resulting in balanced ischemia. 4, 5 Numerous studies have reported that diabetic populations with normal single-photon emission computed tomography (SPECT) or stress echocardiographic assessment may remain at high risk of adverse cardiac events, [6] [7] [8] [9] particularly those who are unable to exercise and require pharmacological stress testing. [10] [11] [12] Stress CMR Risk Stratifies Diabetics Stress perfusion cardiac magnetic resonance imaging (CMR) has shown excellent diagnostic performance for the detection of CAD 13 and is able to assess both diffuse myocardial ischemia and microvascular dysfunction. 14 This study was designed to evaluate the prognostic value of stress perfusion CMR in a consecutive diabetic cohort with suspected myocardial ischemia.
Methods

Study Sample
We performed vasodilator stress perfusion CMR in 173 consecutive patients with diabetes mellitus referred for evaluation of suspected myocardial ischemia. All patients were aged >21 years (range, 29-87 years), and the diagnosis of diabetes mellitus was established according to the current American Diabetics Association guidelines. 15 Exclusion criteria included any typical contraindications to vasodilator stress testing, any metallic hazard for magnetic resonance imaging, prior or known intolerance to gadolinium, severe renal impairment (glomerular filtration rate, <30 mL/min per 1.73 m 2 ), and pregnant state. Before CMR, trained study personnel collected detailed clinical data and medical history using standardized criteria. 16 The institutional ethics review board approved the study, and informed consent was obtained from all patients. This cohort represents a combination of a patient subset from a larger study we have previously published (143 patients; 82.7%), 16 as well as an additional 30 (17.3%) consecutive patients with diabetes mellitus subsequently referred for stress CMR.
Stress CMR Protocol
Before 2006, stress CMR was performed with a 1.5 Tesla scanner (Signa CV/i; General Electric, Milwaukee, WI; 8-element coil), whereas studies after 2006 were conducted with a 3.0 Tesla magnet (Magnetom Trio; Siemens, Erlangen, Germany; 16-element coil). Our standardized stress CMR protocol included stress and rest myocardial perfusion, cine function, and late gadolinium enhancement (LGE) as previously published. 16 All patients were instructed to refrain from caffeinated products 24 hours, and fast 6-hour, before stress CMR. A 12-lead ECG was obtained before and after stress CMR study, and both vital signs and cardiac rhythm were monitored throughout the entire examination. Gating was performed using vectorcardiography or pulse oximetry.
Both stress and rest myocardial perfusion images were acquired at 1.5 Tesla using a saturation-prepared, single-shot spoiled gradient echo sequence (repetition time, 6 ms; echo time, 2.3 ms; echo-train length, 4; acceleration factor of 2 using SENSE; slice thickness, 8 mm) and at 3.0 Tesla using a saturation-recovery prepared turbo fast low-angle single shot sequence (repetition time, 2.4 ms; echo time, 1 ms; acceleration factor of 2 using Generalized Autocalibrating Partially Parallel Acquisitions (slice thickness of 10 mm). A bolus injection of 0.1 mmol/kg of gadolinium-based contrast agent (Magnevist, Bayer, Wayne, NJ) was administered at a rate of 4 to 5 mL/s followed by 20 mL of saline flush at the same injection rate for both stress and rest perfusion imaging. Patients received vasodilator stress with either adenosine (Astellas Pharma US, Deerfield, IL) at a rate of 140 μg/kg per minute for 6 minutes or regadenoson (Astellas Pharma US, Deerfield, IL) with a bolus injection of 0.4 mg. Both stress and rest myocardial perfusion images were acquired at 4 matching slice locations: basal, mid and distal short-axis, in addition to a 4-chamber long axis view. Medical personnel measured the blood pressure of all patient subjects before and after administration of the vasodilator stress agent. Cine imaging was performed in both contiguous short-axis (8 mm, 0 mm spacing) and long-axis views (4-chamber, 2-chamber, and 3-chamber) using steady-state-free precession imaging (repetition time, 3.4 ms; echo time, 1.2 ms; matrix, 256 × 256; slice thickness, 8 mm).
LGE imaging was performed 10 to 15 minutes after rest perfusion imaging using an inversion recovery gradient echo sequence with inversion time chosen to maximally null the septal myocardium.
CMR Image Analysis
Images were uploaded to an offline standard workstation (Mass Clinical 7.4; Medis, Leiden, The Netherlands) for postprocessing and viewing, and the studies were interpreted by the consensus of 2 experienced reviewers (R.Y.K. and B.H.) who were blinded to the clinical and follow-up data of the patients. Perfusion defect(s) consistent with inducible ischemia were defined by >1 segment of subendocardial hypoperfusion, occurring during stress perfusion but not at rest or without matching LGE, persisted for at least 3 phases beyond peak myocardial enhancement, >1 pixel wide, and followed a coronary distribution. 17 Susceptibility artifacts and isolated papillary muscle or epicardial defects were not considered perfusion defects. Segmental analysis for perfusion, regional wall motion abnormalities, and LGE were performed using standard 16-segment American Heart Association model. 18 Inducible ischemia score was calculated by summing the number of segments with inducible ischemia. Infarct volume was quantified from subendocardial LGE imaging using standard criteria of ≥2 SDs of signal intensity beyond normal remote myocardium.
Clinical Outcomes and Follow-Up
Patient follow-up was first performed by a thorough retrospective review of the available electronic medical record, followed by contacting patients using approved standardized study questionnaires. Mortality was also confirmed by the Social Security Death Index. The primary end point of the study was a composite measure of cardiac death or nonfatal MI. Secondary end points included the primary end point in addition to late coronary revascularization (at least 90 days of CMR), and a composite measure, which also included stroke and hospitalization for unstable angina, termed major adverse cardiac events (MACE).
Nonfatal MI was defined from standardized criteria as the presence of a typical rise (>99th percentile over upper limits of normal) and fall of serum cardiac biomarkers (troponin or creatine kinase-MB), along with at least one of the followings: symptoms of ischemia, development of pathological Q waves or ST-segment elevation on 12-lead ECG, or angiographic evidence of CAD. 19 Mortality was confirmed from the medical record and from Social Security Death Index. All cases of mortality were adjudicated by the consensus of 2 study investigators, blinded to all CMR data, as either cardiac (because of acute MI, arrhythmia, or pump failure) or noncardiac. Unstable angina was defined by anginal symptoms requiring hospitalization in the presence of angiographically significant coronary stenosis. Stroke was defined as any event with the development of focal neurological deficits of central origin lasting at least 72 hours and resulting in a physical impairment or radiological evidence of damage consistent with stroke.
Statistical Analysis
Categorical variables were presented as counts with percentages, whereas continuous variables were expressed as mean±SD or as median values with interquartile range depending on normality of distributions. Categorical variables were compared using the Fisher exact test, whereas comparisons for continuous data were performed using 2-sample Student t test or Wilcoxon rank-sum test, where appropriate. Kaplan-Meier analysis was performed for evaluation of MACE-free survival and stratified comparisons were evaluated by the log-rank test. Relationships between hemoglobin A1c (HbA1c) levels and duration of diabetes mellitus with LGE and inducible ischemia score were evaluated with linear regression analysis. Univariable associations with the primary and secondary end points were determined by Cox proportional hazards regression. Multivariable Cox regression analysis was performed using stepwise selection of variables significant on univariable screen and forcing both age and sex into the model a priori. For the evaluation of annualized event rates, the entire cohort was classified into those with inducible ischemia, patients with subendocardial LGE but no inducible ischemia, and those without either inducible ischemia or LGE. A propensity score was generated using a logistic regression model using inducible ischemia as the dependent variable and known risk markers, patient age, sex, history of MI, history of percutaneous coronary intervention, left ventricular (LV) ejection fraction (LVEF), LV end-diastolic volume index, and LV myocardial mass, as independent variables. Multivariable Cox regression analysis was then performed to associate inducible ischemia with the primary end points, adjusting for the propensity score. Net reclassification index was used to evaluate the incremental benefit of inducible ischemia by stress perfusion CMR using 5-year risk categories of 5% (low risk) and 10% (high risk) based on prior studies in diabetics evaluating cardiac risk stratification and guidelines for management. [20] [21] [22] Risk estimates were derived from multivariable Cox regression analysis for the addition of inducible ischemia to a multivariable model containing age, sex, and LVEF.
All statistical analysis was performed using commercially available software (SAS version 9.4; SAS Institute, Cary, NC). A 2-sided P<0.05 was considered statistically significant.
Results
Study Sample
A total of 173 consecutive patients with diabetes mellitus were referred for stress perfusion CMR. All patients successfully underwent diagnostic stress CMR without any major complications, and all studies were of diagnostic quality. Baseline demographics stratified by the presence of inducible ischemia are summarized in Table 1 . Both the mean body mass index and HbA1C for the entire cohort were elevated (31.2±6.9% and 7.9±1.8%, respectively). As expected, the stratum with inducible ischemia was significantly older, had a higher proportion of anginal chest pain, prior history of MI, previous percutaneous coronary intervention and coronary artery bypass grafting surgery, aspirin and β-blocker use, and both ST-abnormalities and T-wave inversions on resting 12-lead electrocardiography.
CMR Characteristics
CMR findings for the entire cohort and stratified by the presence of inducible ischemia are shown in Table 1 . Overall, the diabetic cohort had a relatively preserved LVEF (51.8±18%), 35% of patients had regional wall motion abnormalities, and 51% had the presence of subendocardial LGE. As expected, the stratum with inducible ischemia had a greater proportion of regional wall motion abnormalities, and subendocardial LGE, in addition to a greater burden of global LGE, measured as percentage of the total myocardium. LVEF was significantly lower, and indexed LV end-systolic volume was significantly higher in diabetics with inducible ischemia by CMR. The mean inducible ischemia score in this stratum was 4.8±3.2 segments (16-segment American Heart Association model).
Primary and Secondary Outcomes
Follow-up for clinical events was available for all patients in the cohort for a mean follow-up time of 2.9±2.5 years. In total, there were 13 cases (7.8%) of adjudicated cardiac death and 12 patients (7.2%) had nonfatal MI, with a total of 21 events (12.1%) for the primary end point (4 patients had both nonfatal MI and cardiac death). A total of 38 patients with diabetes mellitus (22%) underwent early revascularization (≤90 days from CMR), 16 (9.3%) underwent late revascularization (>90 days from CMR), 8 (4.8%) had a stroke, and 33 patients (19.9%) were hospitalized for unstable angina.
Kaplan-Meier analysis for survival free from cardiac death or MI, stratified by the presence or absence of inducible ischemia, is shown in Figure 1A . More than 5-year followup, diabetics with no inducible ischemia by CMR had significantly higher event-free survival (P=0.004). Kaplan-Meier analysis stratified by the presence of LGE (green line) or inducible ischemia (red line) for the primary composite end point demonstrated significantly lower event-free survival for both those patients with LGE and diabetes mellitus with inducible ischemia (P=0.006; Figure 1B ).
Annual Event Rates
Estimated annualized event rates for the primary and secondary end points, stratified by the presence of inducible ischemia by CMR, are shown in Figure 2A . The entire cohort experienced an annual rate of cardiac death or nonfatal MI of 4.2%, 6.5% with the addition of late revascularization, and 12.2% for the secondary composite end point of MACE. Diabetics with no inducible ischemia had significantly lower annual event rates for all of the outcome measures, the primary composite end point of cardiac death or MI was 1.4% versus 8.2%, respectively (P=0.0003). Figure 2B displays annualized event rates for the primary and secondary end points of those patients with neither inducible ischemia nor LGE (blue bars),
LGE but no inducible ischemia (green bars), and all diabetics with inducible ischemia (red bars). For the primary composite end point, those patients with diabetes mellitus without inducible ischemia or LGE had very low annual event rates for cardiac or nonfatal MI of 0.5% per year. For all secondary outcome measures, diabetics with LGE had higher annual event rates, whereas those patients with inducible ischemia had the highest annual event rates for both primary and secondary outcomes. There were no differences in annual event rates for either the primary or secondary outcome measures when diabetics with inducible ischemia were stratified by the presence of LGE ( Figure 3 ). Event rates stratified by both presence of inducible ischemia and pretest history of MI are shown in Figure 4 . Although there was no significant difference between annual event rates among patients with no inducible ischemia irrespective of pretest history of MI, diabetics with inducible ischemia and history of MI had the highest event rates among the entire cohort (11.8% versus 6.3%).
Incremental Prognostic Value of Inducible Ischemia
Univariable Cox regression analysis for the primary end point of cardiac death or nonfatal MI is shown in Multivariable Cox regression analysis was performed with stepwise selection of significant univariable predictors after forcing age and sex into the model a priori because of their established prognostic significance in the literature ( Table 2) . 22 Inducible ischemia emerged as the only significant independent 
Association of Inducible Ischemia and LGE with Duration of Diabetes Mellitus and HbA1c
The proportion of patients with inducible ischemia (blue bars) and LGE (red bars) stratified by increasing duration of diabetes mellitus (1-5, 6-10, and >10 years) among our cohort is shown in Figure 5A . There were no statistically significant differences in the prevalence of either inducible ischemia or LGE based on diabetic duration; however, patients with >10-year duration of diabetes mellitus had significantly greater burden of inducible ischemia than those with only 1 to 5 years of diabetes mellitus ( Figure 5B ). There was no association between HbA1c levels and either burden of inducible ischemia (inducible ischemia score) or global LGE (percentage of total myocardium) as shown in Figure 6A and 6B, respectively.
Discussion
The results of this study demonstrate that the presence of inducible ischemia by stress perfusion CMR was associated with an ≈5-fold increased likelihood of cardiac death and nonfatal MI among diabetics. On the contrary, the annual rate of cardiac death and nonfatal MI was low at 0.5% per year among diabetics without inducible ischemia or LGE on CMR. This robust prognostic association between CMR inducible ischemia and hard clinical events was independent of patients' age, sex, and LVEF. The presence of inducible ischemia by stress perfusion CMR was effective in reclassifying >40% of the current diabetic cohort into clinically relevant risk categories.
Cardiovascular disease remains the leading cause of death among diabetics, and the morbidity and mortality from CAD are 2-to 4-fold greater in comparison with nondiabetics. 23, 24 Risk stratification among diabetics with established techniques, including stress echocardiography and SPECT, may have limited sensitivity, particularly for those diabetics unable to undergo exercise assessment. Numerous studies have found high rates of annual cardiac death and nonfatal MI, ranging from 1.9% to 6.0%, among diabetics with normal stress imaging, particularly beyond 2 years. [6] [7] [8] [9] [10] [11] 25, 26 Marwick et al 11 evaluated the prognostic value of stress echocardiography in 937 symptomatic diabetics and reported an annualized mortality rate of 4% in the first 5 years for those with a normal stress echocardiogram. Only 36% of this cohort underwent exercise stress, and referral for a pharmacological test portended a 26 found an annual event rate of 1.9% for those with a normal SPECT and 3-fold increased risk of adverse events for diabetics unable to undergo exercise stress. These results are particularly concerning because of the high proportion of diabetics who have exercise intolerance because of numerous factors, such a peripheral neuropathy, advanced age, skin ulceration, Figure 2 . Estimated annualized event rates in diabetics stratified by the presence or absence of inducible ischemia and late gadolinium enhancement by stress perfusion cardiac magnetic resonance imaging (CMR; n=173). A, Annualized event rates for the primary and secondary outcome measures stratified by the presence (red bars) or absence (blue bars) of inducible ischemia by stress perfusion CMR demonstrate significantly lower annual event rates for both primary and secondary composite outcome measures. B, Annualized event rates for the primary and secondary outcome measures stratified by the presence of late gadolinium enhancement (LGE; green bars), presence of inducible ischemia (red bars), or absence of both LGE and inducible ischemia (blue bars). *P<0.05 for stratified comparisons between event rates. MACE indicates cardiac death, nonfatal MI, late revascularization (>90 d), stroke, and hospitalization for unstable angina; and MI, myocardial infarction. Stress CMR Risk Stratifies Diabetics and peripheral arterial disease. 4 On the basis of these results, some groups have advocated for serial risk stratification every 2 to 3 years in diabetics, 9, 12, 27 which is not highly feasible because of rising costs and prevalence of diabetes mellitus, as well as the risk of cumulative ionizing radiation from SPECT imaging. 28 Patients with diabetes mellitus experience more severe coronary atherosclerosis because of accelerated endothelial dysfunction 29, 30 and are more likely to have silent ischemia with prior ischemic injury at the time of presentation, 31 microvascular dysfunction, 32 and diffuse epicardial coronary disease, 33 which not only portends a worsened prognosis but may also reduce the sensitivity and specificity of established imaging techniques for risk stratification. 34 In this cohort of 173 patients with diabetes mellitus, >30% had resting regional wall motion abnormalities and >50% had evidence of prior MI. Despite these baseline LV abnormalities that may reduce the diagnostic and prognostic performance of both stress echocardiography and SPECT imaging, 12,34 all patients successfully underwent pharmacological stress perfusion CMR, and we observed excellent prognostic use and risk reclassification. Ischemic assessment by stress perfusion CMR is not limited by the presence of balanced ischemia or microvascular dysfunction and is the gold standard for assessment of myocardial fibrosis and identification of prior ischemic injury. Diabetics with a history of pre-existing MI and inducible ischemia had the highest annual rates of cardiac death and MI (11.8%), whereas diabetics without any history of MI or inducible ischemia had significantly lower event rates (1.2% per year; Figure 4 ). The combined assessment of inducible ischemia and subendocardial LGE was able to identify a subgroup of diabetics who enjoyed a very low annual rate of adverse cardiac events and very high event-free survival (cardiac death and nonfatal MI) by Kaplan-Meier analysis. This is in keeping with other studies evaluating the prognostic importance of LGE in patients with silent or clinically unrecognized infarction, 35 as well as the prognostic use of inducible ischemia in higher risk cohorts, such as those with established 16 The combined diagnostic feasibility, prognostic utility, and safety (lack of ionizing radiation) of stress perfusion CMR may provide an effective clinical tool for risk stratification among diabetics with suspicion of cardiovascular disease.
Recent clinical trials evaluating more intensive glycemic control among diabetics have not demonstrated significant reductions in adverse cardiac events, and 1 study even reported an increased risk of cardiac death. [36] [37] [38] Interestingly, we observed no significant association between HbA1c levels and the degree of either inducible ischemia or burden of LGE, expressed as a percentage of the total myocardium ( Figure 5 ). However, patients with a longer duration of diabetes mellitus had a greater burden of inducible ischemia (Figure 6 ), suggesting a link between the degree of atherosclerosis, vascular dysfunction, and duration of diabetes mellitus. Inducible ischemia score by CMR was also an independent predictor of cardiac death and MI in this cohort with an adjusted HR of 1.20 (95% confidence interval, 1.07-1.34; P=0.001) for every 1 additional LV segment (of 16-segment American Heart Association model) with inducible ischemia. The potential reduction in adverse cardiac events by more aggressive medical or invasive therapies in diabetics with greater ischemic burden requires prospective evaluation.
The design of this study was nonrandomized, retrospective, single-center, and had a male preponderance; therefore, the results must be taken into consideration of these inherent limitations. Furthermore, the relatively small sample size reduces the number of covariates that may be included in multivariable analysis to adjust for any confounding. Despite these limitations, the study cohort reflects real-world clinical evaluation of suspected myocardial ischemia in diabetics by clinical cardiologists in a large tertiary care center for >10-year period. In addition, the multivariable model was adjusted for powerful predictors of adverse cardiac events, such as LVEF. A second limitation includes bias introduced by the results of the stress perfusion CMR, which may have Figure 5 . Linear regression analysis between inducible ischemia score and global late gadolinium enhancement (LGE) percentage with hemoglobin A1c (HbA1c) levels (n=173). A, Linear regression analysis between inducible ischemia score (number of segments of 16-segment American Heart Association model with inducible ischemia) and HbA1c levels. B, Linear regression analysis between global subendocardial LGE (percentage of total myocardium) and HbA1c levels. R 2 and P values displayed in image.
Figure 6.
Proportion and burden of inducible ischemia and late gadolinium enhancement (LGE) stratified by duration of diabetes mellitus (n=173). A, Proportion of diabetics with inducible ischemia (blue bars) and late gadolinium enhancement (red bars) stratified by duration of diabetes mellitus (1-5, 6-10, and >10 y). B, Mean inducible ischemia score (number of segments of 16-segment American Heart Association model with inducible ischemia) for different categories of duration of diabetes mellitus (1-5, 6-10, and >10 y). Stress CMR Risk Stratifies Diabetics affected downstream management decisions by referring clinicians. However, when we adjusted our multivariable model for early revascularization, inducible ischemia by stress perfusion CMR remained an independent predictor of our primary outcome measure. Furthermore, as the benefit of revascularization in diabetics with stable angina remains unclear, 39,40 a prospective imaging-guided trial would need to be conducted to determine the impact on cardiovascular outcomes. Finally, this cohort did not include any asymptomatic diabetics, in whom the potential prognostic use of stress perfusion CMR is currently unknown, and the CMR protocol did not allow for quantitative myocardial blood flow analyses that may provide additional prognostic information. Both of these limitations should be topics of future investigation.
In conclusion, stress perfusion CMR was shown to be highly feasible with excellent prognostic use in a high-risk cohort of patients with symptomatic diabetes mellitus who were referred for ischemic assessment. The absence of inducible ischemia and subendocardial LGE by CMR identified patients with diabetes mellitus at low risk for cardiac mortality and nonfatal MI. Further evaluation is required to determine whether early risk stratification may affect downstream cardiac therapies and ultimately lead to improved patient outcomes.
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